Skip to main navigation Skip to search Skip to main content

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel

Research output: Contribution to journal › Article › peer-review

Abstract

The spread of the omicron variant produced an increase in Covid-19 in Israel in late 2021, and a second boost of BNT162b2 vaccine was authorized in early January 2022. This article reports the efficacy of the fourth dose among Israeli citizens 60 years of age or older. Rates of severe illness were reduced by a factor of 3.5 in the fourth week after the second boost.
Original languageEnglish
Pages (from-to)1712-1720
Number of pages9
JournalNew England Journal of Medicine
Volume386
Issue number18
Early online date5 May 2022
DOIs
StatePublished - 5 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

ASJC Scopus subject areas

  • General Medicine

Fingerprint

Dive into the research topics of 'Protection by a Fourth Dose of BNT162b2 against Omicron in Israel'. Together they form a unique fingerprint.

Cite this